Alphaderm 1% & 10%w/w Cream

Alphaderm cream contains the active ingredients Hydrocortisone, PhEur 1% w/w and Urea, BP 10% w/w.

Translucent white cream.

For the treatment of all dry ichthyotic, eczematous conditions of the skin, including atopic, infantile, chronic allergic and irritant eczema, asteatotic, hyperkeratotic and lichenified eczema, neurodermatitis and prurigo.

Adults, children and the elderly. A small amount should be applied topically to the preferably dry affected areas twice daily. In resistant lesions occlusive dressings may be used but this is usually unnecessary because of the self occlusive nature of the special base.

Primary bacterial, viral and fungal diseases of the skin and secondarily infected eczemas or intertrigo acne, perioral dermatitis, rosacea and, in general, should not be used on weeping surfaces.

Known hypersensitivity to the active ingredients or any of its excipients.

Caution should be exercised when using in children. In infants and children, long term continuous therapy should be avoided, as adrenal suppression can occur even without occlusion. Excessive absorption may occur when applied under napkins. Where possible treatment in infants should be limited to 5-7 days.

Application to moist or fissured skin may cause temporary irritation.

As with corticosteroids in general, prolonged application to the face and eyelids is undesirable and the cream should be kept away from the eyes.

None known.

There is inadequate evidence for safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may, therefore, be a very small risk of such effects in the human foetus.

Alphaderm does not interfere with the ability to drive or use machines.

If used correctly Alphaderm is unlikely to cause side effects. However, the following events have been observed with topical steroids, and although are rare with hydrocortisone, may occur, especially with long-term use; spread and worsening of untreated infection; thinning of the skin; irreversible striae atrophicae and telangiectasia; contact dermatitis, perioral dermatitis; acne; mild depigmentation which may be reversible. Atrophic changes may occur in intertriginous areas or nappy areas in young children.

Chronically, grossly excessive over-use on large areas of skin in, for example, children could result in adrenal suppression of the hypothalamic-pituitary axis (HPA) as well as topical and systemic signs and symptoms of high corticosteroid dosage. In such cases, treatment should not stop abruptly. Adrenal insufficiency may require treatment with systemic hydrocortisone. Ingestion of a large amount of Alphaderm would be expected to result in gastrointestinal irritation, nausea, and possibly vomiting. Symptomatic and supportive care should be given. Liberal oral administration of milk or water may be helpful.

Hydrocortisone is a naturally occurring glucocorticoid with proven anti-inflammatory and vasoconstrictive properties. Urea has been demonstrated to have hydrating, keratolytic and anti-pruritic properties. As such, urea has additional therapeutic effect in dry hyperkeratotic skin conditions. Alphaderm cream contains hydrocortisone and urea in a specially formulated base which assists the percutaneous transportation of the active ingredients to the site of action. Due to this formulation, Alphaderm acts as a moderately potent topical corticosteroid. The base is self-occlusive and fulfils the functions of both an ointment and a cream.

Therapeutic activity of hydrocortisone depends upon the adequate penetration through the horny layer of the skin. The urea in the formulation solubilises part of the hydrocortisone and has a keratolytic effect. Both these factors increase penetration of the hydrocortisone

None stated

White soft paraffin, maize starch, isopropyl myristate, sycrowax HR-C, palmitic acid, sorbitan laurate and Arlatone G.

None known.

Two years

Do not store above 25°C.

Supplied in tubes of 30g and 100g.

A patient leaflet is provided with details of use and handling of the product.

Alliance Pharmaceuticals Ltd

Avonbridge House

Bath Road

Chippenham

Wiltshire

SN15 2BB

PL 16853/0060.

13 February 1990

1^st February 2010

POM